OSELTAMIVIR PHOSPHATE and OFF LABEL USE

Overview

OFF LABEL USE is the #1 most commonly reported adverse reaction for OSELTAMIVIR PHOSPHATE, manufactured by Genentech, Inc.. There are 2,050 FDA adverse event reports linking OSELTAMIVIR PHOSPHATE to OFF LABEL USE. This represents approximately 4.7% of all 43,488 adverse event reports for this drug.

Patients taking OSELTAMIVIR PHOSPHATE who experience off label use should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

OFF LABEL USE2,050 of 43,488 reports

OFF LABEL USE is moderately reported among OSELTAMIVIR PHOSPHATE users, representing a notable but not dominant share of adverse events.

Other Side Effects of OSELTAMIVIR PHOSPHATE

In addition to off label use, the following adverse reactions have been reported for OSELTAMIVIR PHOSPHATE:

VOMITING — 2,022 reports
NO ADVERSE EVENT — 1,582 reports
NAUSEA — 1,523 reports
DRUG INEFFECTIVE — 1,216 reports
INFLUENZA — 1,140 reports
DIARRHOEA — 1,012 reports
DYSPNOEA — 966 reports
ABNORMAL BEHAVIOUR — 963 reports
HEADACHE — 900 reports
PYREXIA — 897 reports

Other Drugs Associated with OFF LABEL USE

The following drugs have also been linked to off label use in FDA adverse event reports:

0XYGEN ABACAVIR SULFATE ABATACEPT ABIRATERONE ACETATE ACALABRUTINIB ACETAMINOPHEN ACETAMINOPHEN 500MG ACETAMINOPHEN AND CODEINE ACETAMINOPHEN AND DIPHENHYDRAMINE HYDROCHLORIDE ACETAMINOPHEN AND IBUPROFEN ACETAMINOPHEN AND PHENYLEPHRINE HYDROCHLORIDE ACETAMINOPHEN, ASPIRIN, AND CAFFEINE ACETAMINOPHEN, ASPIRIN, CAFFEINE ACETAMINOPHEN, ASPIRIN (NSAID) AND CAFFEINE ACETAMINOPHEN, CAFFEINE ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE, AND PHENYLEPHRINE HYDROCHLORIDE ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, PHENYLEPHRINE HCL ACETAMINOPHEN, DIPHENHYDRAMINE HYDROCHLORIDE ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE ACETAMINOPHEN, IBUPROFEN

Does OSELTAMIVIR PHOSPHATE cause OFF LABEL USE?

OFF LABEL USE has been reported as an adverse event in 2,050 FDA reports for OSELTAMIVIR PHOSPHATE. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is OFF LABEL USE with OSELTAMIVIR PHOSPHATE?

OFF LABEL USE accounts for approximately 4.7% of all adverse event reports for OSELTAMIVIR PHOSPHATE, making it one of the most commonly reported side effect.

What should I do if I experience OFF LABEL USE while taking OSELTAMIVIR PHOSPHATE?

If you experience off label use while taking OSELTAMIVIR PHOSPHATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.